Inventor · disambiguated record
Kevin Moulder
Also filed as: MOULDER KEVIN
23 granted patents·13 pending applications·90 citations·filing 2005–2025
94Inventor score
Files withTUSK THERAPEUTICS LTD14Black Belt Therapeutics Ltd8DOMANTIS LTD8TOMLINSON IAN M2DOMANTS LTD1
Top patents by PatentIndex Score
36 records- 0197US10752691B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2019·Granted Aug 25, 2020·12 cites·29 claims
- 0296US10745485B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2019·Granted Aug 18, 2020·11 cites·29 claims
- 0396US10738125B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2019·Granted Aug 11, 2020·11 cites·25 claims
- 0496US7563443B2Monovalent anti-CD40L antibody polypeptides and compositions thereofDOMANTIS LTD·Filed 2005·Granted Jul 21, 2009·42 cites·40 claims
- 0585US11787866B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2020·Granted Oct 17, 2023·1 cites·11 claims
- 0685US11697688B2Anti-CD25 for tumour specific cell depletionTUSK THERAPEUTICS LTD·Filed 2019·Granted Jul 11, 2023·1 cites·26 claims
- 0785US7927596B2Methods of antagonizing binding of CD40 to CD40L with CD40L-specific monovalent polypeptidesDOMANTIS LTD·Filed 2009·Granted Apr 19, 2011·5 cites·73 claims
- 0884US7829096B2CD40L-specific monovalent polypeptidesDOMANTIS LTD·Filed 2009·Granted Nov 9, 2010·4 cites·99 claims
- 0976US11236173B2CD38 antibodyBlack Belt Therapeutics Ltd·Filed 2018·Granted Feb 1, 2022·1 cites·17 claims
- 1075US11873341B2Anti-CD25 for tumour specific cell depletionTUSK THERAPEUTICS LTD·Filed 2019·Granted Jan 16, 2024·0 cites·22 claims
- 1175US11851494B2Anti-CD25 for tumour specific cell depletionTUSK THERAPEUTICS LTD·Filed 2019·Granted Dec 26, 2023·0 cites·27 claims
- 1275US11542338B2CD38 modulating antibodyBlack Belt Therapeutics Ltd·Filed 2018·Granted Jan 3, 2023·1 cites·18 claims
- 1375US2025367286A1Cd38 modulating antibody agentsMERCHIERS PASCAL·Filed 2025·Application pending·0 cites
- 1474US11814434B2Anti-CD25 for tumour specific cell depletionTUSK THERAPEUTICS LTD·Filed 2019·Granted Nov 14, 2023·0 cites·26 claims
- 1574US11802161B2Anti-CD25 for tumour specific cell depletionTUSK THERAPEUTICS LTD·Filed 2019·Granted Oct 31, 2023·0 cites·26 claims
- 1674US11802160B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2020·Granted Oct 31, 2023·0 cites·10 claims
- 1773US11919960B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2019·Granted Mar 5, 2024·0 cites·28 claims
- 1872US2024092928A1Cd38 modulating antibodyBlack Belt Therapeutics Ltd·Filed 2023·Application pending·0 cites
- 1969US12162949B2CD38 antibodyBlack Belt Therapeutics Ltd·Filed 2022·Granted Dec 10, 2024·0 cites·12 claims
- 2069US8524236B2Methods of antagonizing the binding of CD40 to CD40L with CD40L-specific monovalent polypeptides in autoimmune individualsGRANT STEVEN·Filed 2005·Granted Sep 3, 2013·1 cites·43 claims
- 2165US2024309101A1Anti-cd25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 2264US12343394B2CD38 modulating antibody agentsBlack Belt Therapeutics Ltd·Filed 2018·Granted Jul 1, 2025·0 cites·19 claims
- 2363US12304964B2CD38 modulating antibodyBlack Belt Therapeutics Ltd·Filed 2022·Granted May 20, 2025·0 cites·16 claims
- 2463US12161717B2CD38 modulating antibody agentsBlack Belt Therapeutics Ltd·Filed 2018·Granted Dec 10, 2024·0 cites·18 claims
- 2563US2008233129A1Ligand that has binding specificity for IL-4 and/or lL-13TOMLINSON IAN M·Filed 2008·Application pending·0 cites
- 2663US2008233130A1Ligand that has binding specificity for IL-4 and/or IL-13TOMLINSON IAN M·Filed 2008·Application pending·0 cites
- 2762US2015087813A1LigandDOMANTIS LTD·Filed 2014·Application pending·0 cites
- 2860US2010234570A1LigandDOMANTIS LTD·Filed 2006·Application pending·0 cites
- 2960US2007093651A1LigandDOMANTIS LTD·Filed 2006·Application pending·0 cites
- 3059US11780930B2CD38 modulating antibodyBlack Belt Therapeutics Ltd·Filed 2018·Granted Oct 10, 2023·0 cites·17 claims
- 3158US2006063921A1LigandDOMANTIS LTD·Filed 2005·Application pending·0 cites
- 3257US2007104710A1Ligand that has binding specificity for IL-4 and/or IL-13DOMANTS LTD·Filed 2006·Application pending·0 cites
- 3356US2010081792A1LigandSMITHKLINE BEECHAM CORP·Filed 2007·Application pending·0 cites
- 3454US2011172400A1Compositions monovalent for cd40l binding and methods of useDOMANTIS LTD·Filed 2010·Application pending·0 cites
- 3549US11879014B2Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibodyTUSK THERAPEUTICS LTD·Filed 2018·Granted Jan 23, 2024·0 cites·16 claims
- 3638US2020283535A1Compounds and methods for tumour-specific cell depletionTUSK THERAPEUTICS LTD·Filed 2018·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →